CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum

作者：Oliver Schnell, Arnav Agarwal, Michel Azizi, Dennis Ballwieser, Katharine Barnard‐Kelly, T Battelino, Dennis Ballwieser, Matthias Blüher, Elisabetta Bugianesi, Ana Cebrian, Antonio Ceriello, Pratik Choudhary, Thomas Danne, Colin M. Dayan, Stefano Del Prato, Robert H. Eckel, Paola Fioretto, T Garvey, J B Green, Hiddo J. L. Heerspink, Rury R. Holman, Baruch Itzhak, S Jacob, Pardeep S. Jhund, L Ji, Parminder K. Judge, Kamlesh Khunti, Marko Korenjak, Andrew J. Krentz, Ekaterini Lambrinou, Peter Libby, J K Mader, J F E Mann, Nikolaus Marx, Chantal Mathieu, John J. V. McMurray, D Müller-Wieland, Nikolaos Papanas, Dipesh Patel, Andreas Pfeiffer, Susanne Reger-Tan, Helena W. Rodbard, Giuseppe M. C. Rosano, Banshi Saboo, Naoki Sato, Scott D. Solomon, Eberhard Standl, Frank Tacke, Pınar Topsever, Christoph Wanner, Sean Wharton, Veronika Young · 发表于：Cardiovascular Diabetology · 年份：2026 · DOI：10.1186/s12933-026-03140-0 · 被引用次数：2 · 研究领域：Diabetes Treatment and Management、Hormonal Regulation and Hypertension、Heart Failure Treatment and Management

The 11th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 20-21, 2025. The Summit provided a multidisciplinary forum to review and discuss recent outcome trials investigating emerging pharmacological therapies targeting diseases of the cardiovascular-kidney-metabolic (CKM) continuum. This report highlights the unique developments of 2025 discussed during the Summit, including the first head-to-head CVOT (SURPASS-CVOT), the growing evidence base for combination therapies across the disease spectrum, new insights into the inflammatory component of the CKM syndrome, and relevant policy developments. The first part of this report summarizes pioneering clinical trials addressing combination therapy with finerenone and empagliflozin (CONFIDENCE), the oral glucagon-like peptide-1 (GLP-1) receptor agonists orforglipron (ATTAIN-1), and the aldosterone synthase inhibitor (ASI) baxdrostat (BaxHTN). The second part presents recent guideline and policy developments discussed by experts in endocrinology, diabetology, cardiology, nephrology, hepatology, and general practice. In addition, advances in medical technology, particularly in continuous glucose and ketone monitoring, are highlighted, as well as emerging therapies for diseases of the CKM continuum. These include pharmacological agents for a broad spectrum of metabolic disorders such as metabolic liver disease and type 1 Diabetes (T1D) alongside emph...